Ulteriori informazioni
Non Small Cell Lung Cancer (NSCLC) is a heterogeneous, complex and most common cause of cancer-related mortality accounting for about 85-87% of lung cancer cases worldwide .Personalized medicine is a tailored therapy that provides a significant precision and positive result for individual patients. It facilitates the choice of most favorable treatment and diminishes "One size fits all" prescribing. The biomarkers help to gain the efficacy of personalized therapy in alleviating the outcomes of a disease. Molecular Diagnostics is the cornerstone in the development of personalized medicine. It is basically the technique, where molecular biology is applied in medical diagnosis to study the molecular processes inside the body. There has been a remarkable development in the field of oncology, after the study of personalized medicine has been evolved as new hope in the treatment of tumors. Since many years, systemic chemotherapy (especially platinum-based doublet chemotherapy) has been the paramount in treating metastatic NSCLC by enhancing the overall survival rate and limiting the toxicities. Recent advancements in treating NSCLC have included histological as well as molecular diagnosis
Info autore
Talath Fatima é uma estudante licenciada em Farmácia na Deccan School of Pharmacy, Hyderabad, e é uma das mais jovens conselheiras editoriais em quatro revistas farmacêuticas. O Dr. Osman Ahmed é um professor de elite em Química Farmacêutica e vice-diretor da Deccan School of Pharmacy, tendo realizado um trabalho de investigação apreciável no domínio da Farmácia.
